Vector BioPharma and iBET collaborate to develop high-throughput analytical methods and scalable processes for gene delivery

AI background business technology, digital transformation

Collaboration set to develop and implement high-throughput analytical methods in support of Vector BioPharma’s CMC (chemistry, manufacturing and controls) development.

China COVID surge not expected to ‘significantly impact’ Europe: WHO

Previous article

What were the risks and patterns of childhood deaths before and during the COVID-19 pandemic?

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in News